Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00619970
Other study ID # CCI-06-00146
Secondary ID
Status Completed
Phase N/A
First received January 25, 2008
Last updated February 15, 2017
Start date February 2007
Est. completion date September 2008

Study information

Verified date February 2017
Source Children's Hospital Los Angeles
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chronic abdominal pain (CAP) is an extremely pervasive childhood condition and, like IBS in adults, it is one of the functional bowel disorders without a clear framework of understanding or an effective treatment. However, new research suggests that small intestinal bacterial overgrowth (SIBO) may be the unifying pathophysiology that explains the variety of symptoms experienced by patients with IBS. As CAP in children is believed to be a precursor to IBS in adults, we hypothesize that children with this disorder have a significantly greater prevalence of small intestinal bacterial overgrowth (SIBO) than normal, healthy children, and that eradication of bacterial overgrowth with antibiotics will reduce symptoms of chronic abdominal pain in children with this condition. To prove this, we will first aim to determine the prevalence of SIBO in both healthy children and those with CAP. We will do this by performing a lactulose breath hydrogen test, the gold standard for the noninvasive measurement of SIBO, on 40 healthy controls and 80 subjects with CAP. We will then assess whether eradication of SIBO with antibiotics will reduce symptoms of chronic abdominal pain in children with this condition. To do this we will randomize, in a double-blinded fashion, the 80 CAP patients to receive a 10-day course of either the antibiotic Rifaximin or a placebo. After completion of the treatment we will evaluate all these patients for eradication of bacterial overgrowth by repeating a lactulose breath hydrogen test. We will also assess for symptom improvement by re-administering questionnaires.


Recruitment information / eligibility

Status Completed
Enrollment 115
Est. completion date September 2008
Est. primary completion date September 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 8 Years to 18 Years
Eligibility Inclusion Criteria:

- Subjects must be between the ages of 8 and 18

- Subjects must be able to swallow pills

- Healthy Controls must be siblings, other family members or friends of the CAP subjects or children who are undergoing an overnight fast in order to obtain AM labs for another purpose other than this study.

- Female CAP subjects who are sexually active or who may become sexually active during the study will be required to practice an effective method of birth control (e.g., oral contraceptives, contraceptive patch or injection, IUD, double barrier method) before entering into the study.

- All CAP subjects must meet the Rome II Criteria for Functional Bowel Disorders Associated with Abdominal Pain or Discomfort in Children

Exclusion Criteria:

Subjects will be excluded if they:

- have a history of inflammatory bowel diseases, diabetes, cirrhosis or other liver disease, juvenile rheumatoid arthritis, systemic lupus, a history of bowel resection (including gastric, small bowel or colon; gallbladder surgery or appendectomy are NOT exclusion criteria).

- have been treated with antibiotics or probiotics within the past 2 months.

- have a history of TB infection or positive Mantoux test performed at screening

- have a history of allergy to rifampin or rifaximin

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Lactulose Breath Test
Healthy controls will receive one lactulose breath test to assess for SIBO
Drug:
xifaxan
xifaxan 550mg TID x10days
placebo
placebo TID x 10days
Procedure:
Lactulose Breath Test
Children with CAP will receive one lactulose breath test to assess for SIBO and one after receiving either Rifaximin or Placebo

Locations

Country Name City State
United States Childrens Hospital Los Angeles Los Angeles California

Sponsors (1)

Lead Sponsor Collaborator
Children's Hospital Los Angeles

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Number of Participants at Baseline With SIBO upon enrollment
Primary Number of Participants With SIBO at Baseline (Week 0) and at 2 Week Post Treatment baseline (week 0) and at 2 weeks post treatment
See also
  Status Clinical Trial Phase
Completed NCT03318614 - Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster Phase 2/Phase 3
Completed NCT02251483 - Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal Bacterial Overgrowth N/A
Withdrawn NCT04244877 - Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility Phase 3
Completed NCT06162702 - Clinical Study of Fecal Microbiota Transplantation in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO) N/A
Completed NCT00680836 - Gulf War Digestive Health Study N/A
Enrolling by invitation NCT03659175 - Characteristic of Intestinal Flora in Male Elderly With Small Intestinal Bacterial Overgrowth
Recruiting NCT04506593 - Indiana University Gastrointestinal Motility Diagnosis Registry
Terminated NCT04316806 - Effect of a Probiotic Formula on Reducing SIBO in IBS Patients N/A
Completed NCT05765994 - Small Intestinal Bacterial Overgrowth in Critically Ill Patients
Not yet recruiting NCT06317441 - The Safety and Efficacy of a Probiotic Intervention on SIBO and Related Gastrointestinal Symptoms N/A
Recruiting NCT05967871 - Pilot Feasibility Study of Fecal Microbiota Transplant for the Treatment of Small Intestinal Bacterial Overgrowth Phase 1
Enrolling by invitation NCT04501380 - Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO) Phase 2
Completed NCT03692299 - Effectiveness of Saccharomyces Boulardii for Gastrointestinal Bacterial-overgrowth in Systemic Sclerosis Phase 4
Completed NCT05915767 - Therapeutic Effect of Olive Leaf Tea on SIBO N/A
Recruiting NCT04910815 - Feasibility of a New Diagnostic Device to Assess Small Intestinal Dysbiosis in Routine Clinical Setting. N/A
Recruiting NCT04499742 - Comparative Assessment of Radioisotope Glucose and Breath Test
Enrolling by invitation NCT02458781 - Antibiotic Treatment Trial for Small Intestinal Bacterial Overgrowth Phase 4
Enrolling by invitation NCT01822470 - Small Intestinal Bacterial Overgrowth: A Prospective Registry
Terminated NCT02439307 - Effycacy of Rifaximin on Reverse Minimal Hepatic Encephalopathy and Elimation Small Intestinal Bacterial N/A
Completed NCT03216239 - SIBO & SIFO After Colectomy